Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.

TitleMultilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.
Publication TypeJournal Article
Year of Publication2016
AuthorsChen, F, Zhang, Y, Şenbabaoğlu, Y, Ciriello, G, Yang, L, Reznik, E, Shuch, B, Micevic, G, De Velasco, G, Shinbrot, E, Noble, MS, Lu, Y, Covington, KR, Xi, L, Drummond, JA, Muzny, DM, Kang, H, Lee, J, Tamboli, P, Reuter, V, Shelley, CSimon, Kaipparettu, BA, Bottaro, DP, Godwin, AK, Gibbs, RA, Getz, G, Kucherlapati, R, Park, PJ, Sander, C, Henske, EP, Zhou, JH, Kwiatkowski, DJ, Ho, TH, Choueiri, TK, Hsieh, JJ, Akbani, R, Mills, GB, A Hakimi, A, Wheeler, DA, Creighton, CJ
JournalCell Rep
Volume14
Issue10
Pagination2476-89
Date Published2016 Mar 15
ISSN2211-1247
KeywordsBasic Helix-Loop-Helix Leucine Zipper Transcription Factors, Carcinoma, Renal Cell, Chromatin, Gene Expression Profiling, Genomics, Humans, Kidney Neoplasms, MicroRNAs, Mutation, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, RNA, Messenger, Signal Transduction, Survival Rate, TOR Serine-Threonine Kinases
Abstract

On the basis of multidimensional and comprehensive molecular characterization (including DNA methalylation and copy number, RNA, and protein expression), we classified 894 renal cell carcinomas (RCCs) of various histologic types into nine major genomic subtypes. Site of origin within the nephron was one major determinant in the classification, reflecting differences among clear cell, chromophobe, and papillary RCC. Widespread molecular changes associated with TFE3 gene fusion or chromatin modifier genes were present within a specific subtype and spanned multiple subtypes. Differences in patient survival and in alteration of specific pathways (including hypoxia, metabolism, MAP kinase, NRF2-ARE, Hippo, immune checkpoint, and PI3K/AKT/mTOR) could further distinguish the subtypes. Immune checkpoint markers and molecular signatures of T cell infiltrates were both highest in the subtype associated with aggressive clear cell RCC. Differences between the genomic subtypes suggest that therapeutic strategies could be tailored to each RCC disease subset.

DOI10.1016/j.celrep.2016.02.024
Alternate JournalCell Rep
PubMed ID26947078
PubMed Central IDPMC4794376
Grant ListCA125123 / CA / NCI NIH HHS / United States
P30 CA016672 / CA / NCI NIH HHS / United States
R21 CA173150 / CA / NCI NIH HHS / United States
P30 CA168524 / CA / NCI NIH HHS / United States
P50 CA101942 / CA / NCI NIH HHS / United States
P01 CA120964 / CA / NCI NIH HHS / United States
P50 CA098258 / CA / NCI NIH HHS / United States
U54 HG003273 / HG / NHGRI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
U24 CA144025 / CA / NCI NIH HHS / United States
U24 CA143843 / CA / NCI NIH HHS / United States
P30 CA125123 / CA / NCI NIH HHS / United States
T32 GM007205 / GM / NIGMS NIH HHS / United States
P30 CA015083 / CA / NCI NIH HHS / United States
F30 CA196089 / CA / NCI NIH HHS / United States
R21 CA179720 / CA / NCI NIH HHS / United States
R21 CA191687 / CA / NCI NIH HHS / United States

Similar Publications